lentivirus-transfected endothelial progenitor cells

Lentivirus-transfected endothelial progenitor cells (EPCs) are autologous or allogeneic EPCs that have been genetically modified using a lentiviral vector to introduce and stably express exogenous genes. This approach is used in experimental cell and gene therapy research to enhance or alter the biological properties of EPCs for therapeutic purposes. The transgene can encode various proteins, such as anti-angiogenic factors (e.g., endostatin), cytokines (e.g., interleukin-10), or growth factors (e.g., VEGF165), depending on the intended application. Lentiviral vectors enable stable integration of the transgene into the host genome, resulting in long-term expression within the transplanted EPC population[1][2][3][4]. These modified cells are being investigated primarily for their potential in treating ischemic diseases, retinal neovascularization, acute lung injury, and other conditions where vascular repair or modulation is beneficial[1][3][4]. The mechanism of action depends on both the inherent regenerative capacity of EPCs and the specific function conferred by the introduced gene.

Other names

lentivirus-modified endothelial progenitor cellsgene-modified EPCs